| Mrs Connie Beiro Freeman, NNP | |
|
1200 S Cedar Crest Blvd, Allentown, PA 18103-6202 | |
| (610) 402-7632 | |
| Not Available |
| Full Name | Mrs Connie Beiro Freeman |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Neonatal, Critical Care |
| Location | 1200 S Cedar Crest Blvd, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114206042 | NPI | - | NPPES |
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
"The National Medical Association believes the passage of health care legislation this weekend will be one of the most important steps Congress can take in securing America's future," remarked Dr. Willarda V. Edwards, president of the National Medical Association. "The NMA is hopeful that Sunday's vote will bring relief to millions of Americans who wonder what will happen to them if they get sick," she continued.
A new Tel Aviv University study examined the brain's reactions in conditions of uncertainty and stressful conflict in an environment of risks and opportunities.
USAID on Monday said it has "delivered the first two of 17 planned laboratory devices" to help quickly diagnose drug-resistant strains of tuberculosis (TB), VOA's "Breaking News" blog reports.
Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.
Array BioPharma Inc. today announced that it has entered into an agreement with Novartis for the worldwide development of the small-molecule MEK inhibitors ARRY-162, currently in a Phase 1 cancer trial, its back-up, ARRY-300, and other MEK inhibitors.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Connie Beiro Freeman, NNP 2100 Mack Blvd Fl 4, Allentown, PA 18103-5622 Ph: (484) 884-4500 | Mrs Connie Beiro Freeman, NNP 1200 S Cedar Crest Blvd, Allentown, PA 18103-6202 Ph: (610) 402-7632 |
News Archive
"The National Medical Association believes the passage of health care legislation this weekend will be one of the most important steps Congress can take in securing America's future," remarked Dr. Willarda V. Edwards, president of the National Medical Association. "The NMA is hopeful that Sunday's vote will bring relief to millions of Americans who wonder what will happen to them if they get sick," she continued.
A new Tel Aviv University study examined the brain's reactions in conditions of uncertainty and stressful conflict in an environment of risks and opportunities.
USAID on Monday said it has "delivered the first two of 17 planned laboratory devices" to help quickly diagnose drug-resistant strains of tuberculosis (TB), VOA's "Breaking News" blog reports.
Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.
Array BioPharma Inc. today announced that it has entered into an agreement with Novartis for the worldwide development of the small-molecule MEK inhibitors ARRY-162, currently in a Phase 1 cancer trial, its back-up, ARRY-300, and other MEK inhibitors.
› Verified 8 days ago